VBI Vaccines - VBIV Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.00
  • Forecasted Upside: 669.23 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.52
▼ -0.04 (-7.14%)

This chart shows the closing price for VBIV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New VBI Vaccines Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VBIV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VBIV

Analyst Price Target is $4.00
▲ +669.23% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for VBI Vaccines in the last 3 months. The average price target is $4.00, with a high forecast of $6.00 and a low forecast of $2.00. The average price target represents a 669.23% upside from the last price of $0.52.

This chart shows the closing price for VBIV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in VBI Vaccines. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/11/2022Raymond JamesDowngradeStrong-Buy ➝ Outperform$5.00 ➝ $2.00Low
8/9/2022Raymond JamesLower TargetStrong-Buy$6.00 ➝ $5.00Low
3/8/2022Raymond JamesLower TargetStrong-Buy$9.00 ➝ $6.00High
12/30/2021Jefferies Financial GroupInitiated CoverageBuy$7.00 ➝ $6.00High
5/21/2021Raymond JamesInitiated CoverageBuyLow
2/25/2021Jefferies Financial GroupInitiated CoverageBuy$7.00High
8/27/2020OppenheimerReiterated RatingBuy$8.00High
8/26/2020Raymond JamesUpgradeOutperform ➝ Strong-Buy$8.00 ➝ $9.00High
7/22/2020Raymond JamesBoost TargetOutperform$3.00 ➝ $8.00High
6/29/2020BMO Capital MarketsReiterated RatingBuy$4.00Low
6/23/2020OppenheimerBoost TargetOutperform$5.00 ➝ $8.00High
5/7/2020OppenheimerReiterated RatingBuy$5.00Medium
11/14/2019Raymond JamesInitiated CoverageOutperform$3.00High
6/19/2019OppenheimerSet TargetBuy$5.00High
6/18/2019BMO Capital MarketsLower TargetOutperform$5.00Low
2/26/2019OppenheimerSet TargetBuy$9.00High
1/16/2019OppenheimerInitiated CoverageOutperform$9.00 ➝ $9.00High
7/27/2018BMO Capital MarketsLower TargetOutperform ➝ Outperform$13.00 ➝ $12.00High
5/10/2018BMO Capital MarketsBoost TargetOutperform$11.00 ➝ $13.00Low
3/23/2018Noble FinancialReiterated RatingBuyHigh
(Data available from 12/1/2017 forward)

News Sentiment Rating

-0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/5/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/4/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/4/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/3/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/2/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/2/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
12/1/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
VBI Vaccines logo
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $0.52
Low: $0.52
High: $0.58

50 Day Range

MA: $0.66
Low: $0.52
High: $0.78

52 Week Range

Now: $0.52
Low: $0.52
High: $3.42

Volume

3,452,882 shs

Average Volume

1,836,672 shs

Market Capitalization

$134.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.83

Frequently Asked Questions

What sell-side analysts currently cover shares of VBI Vaccines?

The following Wall Street sell-side analysts have issued reports on VBI Vaccines in the last year: Jefferies Financial Group Inc., and Raymond James.
View the latest analyst ratings for VBIV.

What is the current price target for VBI Vaccines?

2 Wall Street analysts have set twelve-month price targets for VBI Vaccines in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 669.2%. Jefferies Financial Group Inc. has the highest price target set, predicting VBIV will reach $6.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $2.00 for VBI Vaccines in the next year.
View the latest price targets for VBIV.

What is the current consensus analyst rating for VBI Vaccines?

VBI Vaccines currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VBIV will outperform the market and that investors should add to their positions of VBI Vaccines.
View the latest ratings for VBIV.

What other companies compete with VBI Vaccines?

How do I contact VBI Vaccines' investor relations team?

VBI Vaccines' physical mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company's listed phone number is (617) 830-3031 and its investor relations email address is [email protected] The official website for VBI Vaccines is www.vbivaccines.com. Learn More about contacing VBI Vaccines investor relations.